Walgreens Boots hit by €6.2bn charge over US opioid litigation

Pharmacy giant and rivals CVS Health and Walmart agreed to payout in order to resolve thousands of lawsuits

Boots parent company Walgreens saw demand for for vaccines fall from last year's peak.

Pharmacy giant Walgreens Boots posted a net quarterly loss as it took a $6.5bn (€6.2bn) opioid litigation charge in the US. 

Walgreens and rivals CVS Health and Walmart in November agreed to pay about $13.8bn to resolve thousands of US state and local lawsuits accusing the pharmacy chains of mishandling opioid pain drugs.